Skip to main content
. 2022 Feb 15;12(2):183. doi: 10.3390/metabo12020183

Figure 2.

Figure 2

Meta-analysis of the CV effects in RWS comparing GLP-1RA vs. other GLD (except SGLT-2i). (A). Effect of GLP-1RA vs. other GLD on CV composite outcome; (B). Effect of GLP-1RA vs. other GLD on MACE (CV death, non-fatal MI, or non-fatal stroke); (C). Effect of GLP-1RA vs. other GLD on all-cause death; (D). Effect of GLP-1RA vs. other GLD on HF; (E). Effect of GLP-1RA vs. other GLD on MI; (F). Effect of GLP-1RA vs. other GLD on stroke; (G). Effect of GLP-1RA vs. other GLD on CV death; (H). Effect of GLP-1RA vs. other GLD on PAD. GLP-1RA, glucagon-like peptide-1 receptor agonists; GLD, glucose-lowering drugs; SGLT-2i, sodium-glucose transporter-2 inhibitors; CV, cardiovascular; MACE, major adverse cardiovascular events; HF, heart failure; MI, myocardial infarction; PAD, peripheral arterial disease.